Back to search

Peptide record

TPDB92268

IR13 Antibacterial Anticancer Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92268
IR13
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia and CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
CIIRRIIRRIIRR-NH2
Physicochemical Analysis
C75H145N31O14S1
ANDEQGHLKMFPSTWYV
RI
1737.24
12.70
6
0
6
+6
2.76
0.192
180.00
Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
0
A
6
R
0
N
0
D
1
C
0
E
0
Q
0
G
0
H
6
I
0
L
0
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 6 N: 0 D: 0 C: 1 E: 0 Q: 0 G: 0 H: 0 I: 6 L: 0 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
13
C75H145N31O14S1
1737.24
12.70
+6
2.76
0.192
Amidation
L
Linear
Free
Anticancer
Synthetic
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 > 100 µM
Anticancer
100 µM

Target

Colorectal Cancer
HCT-116
Colon

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 > 100 µM
Anticancer
100 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022